(3R)- ((2,3- dihydro- 5- methyl- 3- ((4- morpholinyl)methyl)pyrrolo- (1,2,3- de)- 1,4- benzoxazin- 6- yl)(1- naphthalenyl))methanone (WIN 55,212)

a cannabinoid agonist; aminoalkylindole analog

Also Known As:

WIN 55,212; ((3R)-2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo(1,2,3-de)-1,4-benzoxazin-6-yl)-1-naphthalenyl-methanone, methanesulfonate (1:1); (+)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone monomethanesulfonate; (2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl)methanone monomethanesulfonate; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone monomethanesulfonate; (3S)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; (R)-(+)-WIN 55212-2 mesylate; (R)-(+)-WIN-55212-2; (R)-WIN-55212; 2,3-dihydro-5-methyl-3((4-morpholinyl)methyl) pyrrolo(1,2,3,-de)-1,4-benzoxazin-6-yl)-1-naphthalenyl methanone; WIN 55.212-2; WIN 55212; WIN 55212-2 mesylate; WIN 55212-3; WIN-55212; WIN55212-2; Win 55212-2; Win-55212-2

Networked: 216 relevant articles (18 outcomes, 36 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Adler, Martin W: 8 articles (08/2009 - 06/2002)
2.	Geller, Ellen B: 7 articles (08/2009 - 06/2002)
3.	Luszczki, Jarogniew J: 5 articles (03/2015 - 04/2011)
4.	Ulugol, Ahmet: 4 articles (07/2020 - 11/2004)
5.	Martín, María Isabel: 4 articles (08/2012 - 11/2005)
6.	Rawls, Scott M: 4 articles (08/2007 - 06/2002)
7.	Di Giovanni, Giuseppe: 3 articles (01/2022 - 01/2019)
8.	Gunduz, Ozgur: 3 articles (07/2020 - 10/2011)
9.	Wagner, Edward J: 3 articles (03/2015 - 01/2009)
10.	Florek-Luszczki, Magdalena: 3 articles (03/2015 - 12/2011)

Related Diseases

1.	Hyperalgesia 12/01/2021 - "Additionally, WIN 55,212-2 increased CB1 in DRG, reduced mechanical hyperalgesia, cold allodynia and c-Fos expression in DRG and SC. " 12/01/2006 - "At the dose of 0.125 mg/kg iv, WIN 55,212-2 reversed the hyperalgesia produced by nerve injury. " 06/01/2004 - "injection of WIN 55,212-2 into the contralateral paw did not alter the heat-injury induced hyperalgesia, suggesting that the antihyperalgesia occurred through a peripheral mechanism. " 06/01/2004 - "The inactive enantiomer WIN 55,212-3 did not alter mechanical or heat hyperalgesia, suggesting the effects of WIN 55,212-2 were receptor-mediated. " 06/01/2004 - "WIN 55,212-2 attenuated both heat and mechanical hyperalgesia dose-dependently. "
2.	Pain (Aches) 01/01/2009 - "The current study assessed the efficacy of the CB receptor agonist WIN 55,212-2 (WIN) in a rat model of neuropathic SCI pain. " 06/01/2021 - "Microinjection of WIN 55,212-2 into the NC significantly reduced pain responses in a dose-dependent manner. " 04/01/2016 - "The effect of spinally administered WIN 55,212-2, a cannabinoid agonist, on thermal pain sensitivity in diabetic rats." 12/01/2012 - "Selective cannabinoid receptor agonists, such as WIN 55212-2, appear to have a favorable action in limiting cell proliferation and in controlling pain symptoms. " 12/01/2011 - "Whereas intracerebroventricular (i.c.v.) injection of WIN 55,212-2 reduced pain-related behaviors in the formalin test, interestingly, i.c.v. HE increased behaviors. "
3.	Hypothermia 12/01/1992 - "Stereoselectivity was demonstrated by the fact that (+)-WIN-55,212 (one isomer of a semirigid derivative possessing C2-H and C3-naphthoyl substituents) was moderately potent in all tests (ED50 values ranging from 0.25-23 mumol/kg), but (-)-WIN-55,212 was inactive up to 57 mumol/kg. Active aminoalkylindole compounds were generally least effective in the production of hypothermia. " 12/28/2006 - "WIN 55212-2 (1, 2.5, 5 and 10 mg/kg, i.m.) caused a significant hypothermia. " 05/01/2004 - "WIN 55212-2 (2.5 mg/kg im) produced a rapid hypothermia that peaked 45-90 min postinjection. " 02/01/2004 - "WIN 55212-2 (1-5 mg/kg, i.m.) produced dose-dependent hypothermia that peaked 45 to 90 min post-injection. " 10/01/2002 - "WIN 55212-2 (1-10 mg/kg i.m.) produced dose-dependent hypothermia that peaked 60 to 180 min postinjection. "
4.	Spinal Cord Injuries (Spinal Cord Injury) 09/15/2017 - "The synthetic cannabinoid WIN55212-2 ameliorates traumatic spinal cord injury via inhibition of GAPDH/Siah1 in a CB2-receptor dependent manner." 01/01/2019 - "The aim of the study was to examine whether the cannabinoid agonist WIN55212-2 could attenuate ischemic spinal cord injury (SCI) in rats through inhibition of GAPDH/Siah1 signaling. " 03/01/2007 - "Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injury." 12/01/2010 - "Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain." 01/01/2009 - "Sustained antinociceptive effect of cannabinoid receptor agonist WIN 55,212-2 over time in rat model of neuropathic spinal cord injury pain."
5.	Hypersensitivity (Allergy) 03/01/2007 - "The current study evaluated the efficacy of the nonselective CB receptor agonist WIN 55,212-2 on tactile hypersensitivity in rats following a brief compression to the thoracic spinal cord. " 01/05/2009 - "Using the same paradigm, WIN 55,212-2 was then tested against the synaptically-induced nociceptive hypersensitivity in response to noxious thermal stimulation of the tail (hot water tail immersion). " 05/01/2007 - "When delivered to the contralateral side to injury, WIN 55,212-2 (1.4 or 2.8 microg microl(-1) hr(-1)) did not significantly affect nerve injury-associated hypersensitivity. " 05/01/2007 - "Compared with vehicle treatment, WIN 55,212-2 (1.4 microg microl(-1) hr(-1)) reduced hypersensitivity to stimuli applied to the injured limb at 2, 4 and 6 days after injury. " 01/05/2009 - "Further, WIN 55,212-2 blocked the nociceptive hypersensitivity induced by intrathecal administration of substance P. "

Related Drugs and Biologics

1.	Cannabinoid Receptor Agonists
2.	CB1 Cannabinoid Receptor (CB1 Receptor)
3.	CB2 Cannabinoid Receptor
4.	Cannabinoids
5.	AM 251 (AM251)
6.	iodopravadoline (AM 630)
7.	Rimonabant
8.	Cannabinoid Receptors (Cannabinoid Receptor)
9.	Dronabinol (THC)
10.	HU 211 (HU 210)

Related Therapies and Procedures

1.	Topical Administration
2.	Therapeutics
3.	Analgesia
4.	Injections
5.	Induced Hypothermia